Hyloris Pharmaceuticals SA announced that it has entered into an exclusive, worldwide licensing agreement with Rhoshan Pharmaceuticals Inc. (“Rhoshan”), to develop, manufacture and commercialise intravenous acetylsalicylic acid (previously known as Hyloris’ HY-073) for the treatment of patients with suspected acute coronary syndromes (ACS). Acetylsalicylic acid IV is currently not available in the U.S. and Hyloris anticipates commercialising the product in the U.S. with its own future sales force targeting cardiologists in the hospital setting. Coronary heart disease (CHD) is a common term for the build-up of plaque in the heart’s arteries, and is the leading cause of mortality in the U.S.1 CHD can lead to ACS, life-threatening conditions that account for 50% of all cardiovascular disease-related deaths, including acute myocardial infarction (heart attack), unstable angina (chest pain that may signal an impending heart attack) or sudden cardiac death. About 2 million patients with acute myocardial infarction and unstable angina are admitted to the hospital each year in the U.S. Under the terms of the agreement with Rhoshan, Hyloris acquires an exclusive worldwide license to all intellectual property rights, knowhow, and technical proprietary information in relation to the IV formulation technology (U.S. patent granted on 31 March 2021) to develop intravenous acetylsalicylic acid in multiple indications. Hyloris will be responsible for the manufacturing and commercialisation of the product, whereas Rhoshan will continue product development and regulatory affairs activities, and will bear the NDA submission costs. Rhoshan will receive an upfront payment of $750,000; and is eligible to receive $1.25 million development and regulatory milestones; commercial-based milestones, as well as a share of net profit. Hyloris will provide maximum $7.5 million in R&D funding up to, and including, regulatory approval.